Gilead Teases Big Cancer Drug Readouts In Second Half

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.

Cancer cells on scientific background.3d illustration
Gilead announced its second quarter earnings, highlighting developments in virology as well as oncology • Source: Shutterstock

Although antivirals remain the cornerstone of Gilead Sciences, Inc.’s overall business, including its COVID-19 drug Veklury (remdesivir), the second quarter also saw continued significant growth for its oncology business, led by its cell therapies and a recently approved breast cancer drug. The company, which has been focusing on building oncology as a franchise to diversify from antivirals, expects to reveal important cancer data readouts through the end of 2021.

The Foster City, CA-based company announced its second-quarter earnings on 29 July, reporting overall revenues that grew 21% to $6.2bn...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.